ArticleAlzheimer disease and associated disorders
Community engagement in diverse populations for Alzheimer disease prevention trials.
Article in Alzheimer disease and associated disorders. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer's Disease Clinical Trials; A Rapid Review.The journal of prevention of Alzheimer's disease · 2024Pooled it
- Challenging Assumptions About African American Participation in Alzheimer Disease Trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2017Pooled it
- Dementia registries around the globe and their applications: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Pooled it
- Trial
- Evaluating evidence-based recruitment strategies for Alzheimer's disease and related dementias clinical trial research: A literature review.The journal of prevention of Alzheimer's disease · 2026Review
- A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce.JAMA network open · 2024Observational
- US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.The journal of prevention of Alzheimer's disease · 2023Article
- Modifiable Barriers for Recruitment and Retention of Older Adults Participants from Underrepresented Minorities in Alzheimer's Disease Research.Journal of Alzheimer's disease : JAD · 2021Review
- "From Victimhood to Warriors": Super-researchers' Insights Into Alzheimer's Disease Clinical Trial Participation Motivations.The Gerontologist · 2020Article
- Depression screening in cognitively normal older adults: Measurement bias according to subjective memory decline, brain amyloid burden, cognitive function, and sex.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- Effects of pioglitazone on mnemonic hippocampal function: A blood oxygen level-dependent functional magnetic resonance imaging study in elderly adults.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review.Alzheimer's & dementia (New York, N. Y.) · 2019Review
- Dual-Task Gait and Alzheimer's Disease Genetic Risk in Cognitively Normal Adults: A Pilot Study.Journal of Alzheimer's disease : JAD · 2018Article
- Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience.Alzheimer's & dementia (New York, N. Y.) · 2018Review
- Recruiting to preclinical Alzheimer's disease clinical trials through registries.Alzheimer's & dementia (New York, N. Y.) · 2017Article
- African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials.Alzheimer's & dementia (New York, N. Y.) · 2017Article
- Attitudes toward Potential Participant Registries.Journal of Alzheimer's disease : JAD · 2017Article
- A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.Alzheimer's & dementia (New York, N. Y.) · 2016Article
- Alzheimer Disease Worries, Fears, and Stigma and Their Relationship to Genetic and Interventional Research Engagement.Alzheimer disease and associated disordersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The recruitment of asymptomatic volunteers has been identified as a critical factor that is delaying the development and validation of preventive therapies for Alzheimer disease (AD). Typical recruitment strategies involve the use of convenience samples or soliciting participation of older adults with a family history of AD from clinics and outreach efforts. However, high-risk groups, such as ethnic/racial minorities, are traditionally less likely to be recruited for AD prevention studies, thus limiting the ability to generalize findings for a significant proportion of the aging population. A community-engagement approach was used to create a registry of 2311 research-ready, healthy adult volunteers who reflect the ethnically diverse local community. Furthermore, the registry's actual commitment to research was examined, through demonstrated participation rates in a clinical study. The approach had varying levels of success in establishing a large, diverse pool of individuals who are interested in participating in pharmacological prevention trials and meet the criteria for primary prevention research trials designed to delay the onset of AD. Our efforts suggest that entry criteria for the clinical trials need to be carefully considered to be inclusive of African Americans, and that sustained effort is needed to engage African Americans in pharmacological prevention approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.